SER (Serina Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 04, 2026)


SER Serina Therapeutics Inc SER
12 GF Score
Price $1.90
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics 5-Year Yield-on-Cost %?

Serina Therapeutics SER -1.04% 12 5-Year Yield-on-Cost % is 0.00 as of Jul. 04, 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 153 Biotechnology companies, Serina Therapeutics ranks worse than 653594.12% on this metric.

Serina Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Serina Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



SER's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.72
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Serina Therapeutics  (AMEX:SER) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Serina Therapeutics 5-Year Yield-on-Cost % Related Terms


SER vs NRSN, IGC, PVCT: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Serina Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's 5-Year Yield-on-Cost % falls into.


SER
12GF Score
Serina Therapeutics Inc SER
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Serina Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Serina Therapeutics (SER) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Serina Therapeutics and its competitors. According to the industry distribution chart, Serina Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry.
Is Serina Therapeutics' 5-Year Yield-on-Cost % too high?
Serina Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Serina Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' 5-Year Yield-on-Cost % compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Serina Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.72, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Serina Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Serina Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Serina Therapeutics (SER), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges 2BO:Germany
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score

Get the complete analysis for SER

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.90
Price